Comparing two antiviral treatments during immunotherapy for liver cancer
Part of Cancer, Digestive system, Infections clinical trials.
This study compares two ways of managing hepatitis B while you receive immunotherapy for liver cancer: one group gets a single antiviral drug (TAF), the other gets two antiviral drugs (ETV and TAF). The goal is to see which approach better supports the immunotherapy and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have had hepatitis B for at least 6 months and have a high viral load (2,000 IU/mL or more)
- You have liver cancer that can't be removed with surgery or has spread, and you are able to get around normally (ECOG 0-1)
- You are scheduled to receive immunotherapy as your main treatment
- You do not have hepatitis C or HIV, and you have not had an organ transplant
- Your heart, kidneys, and immune system are in good enough shape for immunotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving antiviral medicine after liver cancer treatment helps prevent the cancer from coming back and improves overall outcomes. It is for people with hepatitis B who have had their liver cancer removed or destroyed with a procedure.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This trial tests whether adding two immunotherapy drugs (tremelimumab and durvalumab) to a standard liver cancer treatment called TACE can help people with liver cancer that cannot be removed by surgery. TACE uses tiny particles to block the blood supply to the tumor and delivers chemotherapy directly to the liver.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.